Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules

ACS Chemical Biology

Volumn 10, Issue 10, 2015, Pages 2246-2256

  Urick, Andrew K ^a   Hawk, Laura M L ^a   Cassel, Melissa K ^a   Mishra, Neeraj K ^a   Liu, Shuai ^b   Adhikari, Neeta ^c   Zhang, Wei ^b   Dos Santos, Camila O ^d   Hall, Jennifer L ^c   Pomerantz, William C K ^a  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Cold Spring Harbor Laboratory ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN INHIBITOR; GSK 1379725A; GSK 1379746A; GSK 1379767A; GSK 260205A; GSK 561866B; PROTEIN; PROTEIN BPTF; PROTEIN BRD4; SB 242719; SB 284851BT; SB 284852BT; SB 590885AAE; TRYPTOPHAN; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; CELL NUCLEUS ANTIGEN; ENZYME INHIBITOR; FETAL ALZHEIMER ANTIGEN; FLUORINE; NERVE PROTEIN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANISOTROPY; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIFFERENTIAL SCANNING FLUORIMETRY; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; FLUORINE NUCLEAR MAGNETIC RESONANCE; FLUOROMETRY; HUMAN; HUMAN CELL; ISOTHERMAL TITRATION CALORIMETRY; LIGAND BINDING; MOLECULAR LIBRARY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; THERMOSTABILITY; TOXICITY TESTING; X RAY CRYSTALLOGRAPHY; BINDING COMPETITION; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; IC50; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECLINICAL STUDY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION; TEMPERATURE;

ANTIGENS, NUCLEAR; BINDING, COMPETITIVE; CELL LINE; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FLUORINE; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE IMAGING; MOLECULAR STRUCTURE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; TRANSCRIPTION FACTORS;

EID: 84944769253     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b00483     Document Type: Article

References (44)

1. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., and Schapira, M. (2012) Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 11, 384-400 10.1038/nrd3674
2. Filippakopoulos, P. and Knapp, S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation Nat. Rev. Drug Discovery 13, 337-56 10.1038/nrd4286
3. Dar, A. A., Nosrati, M., Bezrookove, V., de Semir, D., Majid, S., Thummala, S., Sun, V., Tong, S., Leong, S. P. L., Minor, D., Billings, P. R., Soroceanu, L., Debs, R., Miller, J. R., Sagebiel, R. W., and Kashani-Sabet, M. (2015) The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy JNCI J. Natl. Cancer Inst. 107, djv034-djv034 10.1093/jnci/djv034
4. Buganim, Y., Goldstein, I., Lipson, D., Milyavsky, M., Polak-Charcon, S., Mardoukh, C., Solomon, H., Kalo, E., Madar, S., Brosh, R., Perelman, M., Navon, R., Goldfinger, N., Barshack, I., Yakhini, Z., and Rotter, V. (2010) A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype PLoS One 5, e9657 10.1371/journal.pone.0009657
5. Xiao, S., Liu, L., Lu, X., Long, J., Zhou, X., and Fang, M. (2015) The prognostic significance of bromodomain PHD-finger transcription factor in colorectal carcinoma and association with vimentin and E-cadherin J. Cancer Res. Clin. Oncol. 141, 1465 10.1007/s00432-015-1937-y
6. Kim, K., Punj, V., Choi, J., Heo, K., Kim, J.-M., Laird, P. W., and An, W. (2013) Gene dysregulation by histone variant H2A.Z in bladder cancer Epigenet. Chromatin 6, 34 10.1186/1756-8935-6-34
7. Ruthenburg, A. J., Li, H., Milne, T. a, Dewell, S., McGinty, R. K., Yuen, M., Ueberheide, B., Dou, Y., Muir, T. W., Patel, D. J., and Allis, C. D. (2011) Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions Cell 145, 692-706 10.1016/j.cell.2011.03.053
8. Chung, C.-W. and Witherington, J. (2011) Progress in the discovery of small-molecule inhibitors of bromodomain - histone interactions J. Biomol. Screening 16, 1170-85 10.1177/1087057111421372
9. Borah, J. C., Mujtaba, S., Karakikes, I., Zeng, L., Muller, M., Patel, J., Moshkina, N., Morohashi, K., Zhang, W., Gerona-Navarro, G., Hajjar, R. J., and Zhou, M. M. (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes Chem. Biol. 18, 531-541 10.1016/j.chembiol.2010.12.021
10. Harner, M. J., Chauder, B. A., Phan, J., and Fesik, S. W. (2014) Fragment-based screening of the bromodomain of ATAD2 J. Med. Chem. 57, 9687-9692 10.1021/jm501035j
11. Ferguson, F. M., Dias, D. M., Rodrigues, J., Wienk, H., Boelens, R., Bonvin, A., Abell, C., and Ciulli, A. (2014) Binding Hotspots of BAZ2B Bromodomain: Histone Interaction Revealed by Solution NMR Driven Docking Biochemistry 53, 6706-6716 10.1021/bi500909d
12. Dalvit, C., Fagerness, P. E., Hadden, D. T. A., Sarver, R. W., and Stockman, B. J. (2003) Fluorine-NMR experiments for high-throughput screening: Theoretical aspects, practical considerations, and range of applicability J. Am. Chem. Soc. 125, 7696-7703 10.1021/ja034646d
13. Pomerantz, W. C., Wang, N., Lipinski, A. K., Wang, R., Cierpicki, T., and Mapp, A. K. (2012) Profiling the dynamic interfaces of fluorinated transcription complexes for ligand discovery and characterization ACS Chem. Biol. 7, 1345-50 10.1021/cb3002733
14. Gee, C. T., Koleski, E. J., and Pomerantz, W. C. K. (2015) Fragment Screening and Druggability Assessment for the CBP/p300 KIX Domain through Protein-Observed 19F NMR Spectroscopy Angew. Chem., Int. Ed. 54, 3735-3739 10.1002/anie.201411658
15. Curtis-Marof, R., Doko, D., Rowe, M. L., Richards, K. L., Williamson, R. A., and Howard, M. J. (2014) F-19 NMR spectroscopy monitors ligand binding to recombinantly fluorine-labelled bx from human protein disulphide isomerase (hPDI) Org. Biomol. Chem. 12, 3808-3812 10.1039/c4ob00699b
16. Marsh, E. N. G. and Suzuki, Y. (2014) Using 19F NMR to probe biological interactions of proteins and peptides ACS Chem. Biol. 9, 1242-1250 10.1021/cb500111u
17. Ge, X., MacRaild, C. A., Devine, S. M., Debono, C. O., Wang, G., Scammells, P. J., Scanlon, M. J., Anders, R. F., Foley, M., and Norton, R. S. (2014) Ligand-Induced Conformational Change of Plasmodium falciparum AMA1 Detected Using F-19 NMR J. Med. Chem. 57, 6419-6427 10.1021/jm500390g
18. Mishra, N. K., Urick, A. K., Ember, S. W. J., Schonbrunn, E., and Pomerantz, W. C. (2014) Fluorinated Aromatic Amino Acids Are Sensitive 19F NMR Probes for Bromodomain-Ligand Interactions ACS Chem. Biol. 9, 2755-2760 10.1021/cb5007344
19. Zartler, E. R., Hanson, J., Jones, B. E., Kline, A. D., Martin, G., Mo, H., Shapiro, M. J., Wang, R., Wu, H., and Yan, J. (2003) RAMPED-UP NMR: Multiplexed NMR-based screening for drug discovery J. Am. Chem. Soc. 125, 10941-10946 10.1021/ja0348593
20. Ember, S. W. J., Zhu, J. Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., and Schönbrunn, E. (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors ACS Chem. Biol. 9, 1160-1171 10.1021/cb500072z
21. Ciceri, P., Müller, S., OMahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. a, Pallares, G., Picaud, S., Wells, C., Martin, S., Wodicka, L. M., Shah, N. P., Treiber, D. K., and Knapp, S. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Nat. Chem. Biol. 10, 305-12 10.1038/nchembio.1471
22. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. a, Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains Nature 468, 1067-73 10.1038/nature09504
23. Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletar, I., Ciulli, A., Knapp, S., and Heightman, T. D. (2011) Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery Mol. BioSyst. 7, 2899-2908 10.1039/c1mb05099k
24. Drewry, D. H., Willson, T. M., and Zuercher, W. J. (2014) Seeding Collaborations to Advance Kinase Science with the GSK Published Kinase Inhibitor Set (PKIS) Curr. Top. Med. Chem. 14, 340-342 10.2174/1568026613666131127160819
25. Bryant, R. G. (1983) The NMR Time Scale J. Chem. Educ. 60, 933 10.1021/ed060p933
26. Mishra, N. K., Urick, A. K., Ember, S. W., Schonbrunn, E., and Pomerantz, W. C. (2014) Fluorinated Aromatic Amino Acids Are Sensitive F NMR Probes for Bromodomain-Ligand Interactions ACS Chem. Biol. 9, 2755-2760 10.1021/cb5007344
27. Vidler, L. R., Brown, N., Knapp, S., and Hoelder, S. (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites J. Med. Chem. 55, 7346-59 10.1021/jm300346w
28. Zhang, Z. J., Kwiatkowski, N., Zeng, H., Lim, S. M., Gray, N. S., Zhang, W., and Yang, P. L. (2012) Leveraging kinase inhibitors to develop small molecule tools for imaging kinases by fluorescence microscopy Mol. BioSyst. 8, 2523-2526 10.1039/c2mb25099c
29. Chung, C.-W., Dean, A. W., Woolven, J. M., and Bamborough, P. (2012) Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery J. Med. Chem. 55, 576-86 10.1021/jm201320w
30. Drouin, L., McGrath, S., Vidler, L. R., Chaikuad, A., Monteiro, O., Tallant, C., Philpott, M., Rogers, C., Fedorov, O., Liu, M. J., Akhtar, W., Hayes, A., Raynaud, F., Muller, S., Knapp, S., and Hoelder, S. (2015) Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B J. Med. Chem. 58, 2553-2559 10.1021/jm501963e
31. Takle, A. K., Brown, M. J. B., Davies, S., Dean, D. K., Francis, G., Gaiba, A., Hird, A. W., King, F. D., Lovell, P. J., Naylor, A., Reith, A. D., Steadman, J. G., and Wilson, D. M. (2006) The identification of potent and selective imidazole-based inhibitors of B-Raf kinase Bioorg. Med. Chem. Lett. 16, 378-381 10.1016/j.bmcl.2005.09.072
32. Boehm, J. C., Bower, M. J., Gallagher, T. F., Kassis, S., Johnson, S. R., and Adams, J. L. (2001) Phenoxypyrimidine inhibitors of p38 alpha kinase: Synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-2-phenoxypyrimidin-4-yl) imidazoles Bioorg. Med. Chem. Lett. 11, 1123-1126 10.1016/S0960-894X(01)00163-9
33. Dixon, S. L., Smondyrev, A. M., and Rao, S. N. (2006) PHASE: A novel approach to pharmacophore modeling and 3D database searching Chem. Biol. Drug Des. 67, 370-372 10.1111/j.1747-0285.2006.00384.x
34. Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., and Friesner, R. a. (2006) PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results J. Comput.-Aided Mol. Des. 20, 647-671 10.1007/s10822-006-9087-6
35. Small-Molecule Drug Discovery Suite 2014-2: Phase, version 3.9; Schrödinger, LLC: New York, 2014.
36. Cho, A. E., Guallar, V., Berne, B. J., and Friesner, R. (2005) Importance of accurate charges in molecular docking: Quantum Mechanical/Molecular Mechanical (QM/MM) approach J. Comput. Chem. 26, 915-931 10.1002/jcc.20222
37. Small-Molecule Drug Discovery Suite 2014-2: Schrödinger Suite 2014-2 QM-Polarized Ligand Docking protocol; Glide, version 6.3; Schrödinger, LLC, New York, NY, 2014. Jaguar, version 8.4; Schrödinger, LLC: New York, 2014. QSite, version 6.3; Schrödinger, LLC: New York, 2014.
38. Fersht, A. (1999) Structure and Mechanism in Protein Science, Freeman, New York.
39. Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V. S., Kumar, V., Hasan, S., Brown, J. R., Peishoff, C. E., Cardon, L. R., and Garcia-Bustos, J. F. (2010) Thousands of chemical starting points for antimalarial lead identification Nature 465, 305-310 10.1038/nature09107
40. Montesano, R., Soriano, J. V., Fialka, I., and Orci, L. (1998) Isolation of EpH4 mammary epithelial cell subpopulations which differ in their morphogenetic properties In Vitro Cell. Dev. Biol.: Anim. 34, 468-477 10.1007/s11626-998-0080-3
41. Muchmore, D. C., McIntosh, L. P., Russell, C. B., Anderson, D. E., and Dahlquist, F. W. (1989) Nuclear Magnetic Resonance Part B Structure and Mechanism, In Methods Enzymol., Elsevier: Amsterdam.
42. Crowley, P. B., Kyne, C., and Monteith, W. B. (2012) Simple and inexpensive incorporation of 19F-tryptophan for protein NMR spectroscopy Chem. Commun. 48, 10681-3 10.1039/c2cc35347d
43. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G., and Gray, T. (1995) How to measure and predict the molar absorption coefficient of a protein Protein Sci. 4, 2411-23 10.1002/pro.5560041120
44. Huang, X. (2003) Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand J. Biomol. Screening 8, 34-8 10.1177/1087057102239666